Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Cited by (1,000)

Items 101–200 of 1,000

1. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
   Collin Michael Blakely, Anatoly Urisman, Matthew A. Gubens, Claire K. Mulvey, Greg M. Allen, STEPHEN C. SHIBOSKI, Julia K. Rotow, Turja Chakrabarti, Daniel Lucas Kerr, Jacqueline V. Aredo et al. · 2024 · Journal of Clinical Oncology
2. Pulmonary toxicity of immune checkpoint immunotherapy
   Mohammad Ghanbar, Karthik S. Suresh · 2024 · Journal of Clinical Investigation
3. Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
   Samuel Rosner, Joshua E. Reuss, MARIANNA L. ZAHURAK, Jiajia Zhang, Zhen Zeng, Janis Marie Taube, Valsamo Anagnostou, Kellie Nicole Smith, Joanne Riemer, Peter Bela Illei et al. · 2023 · Clinical Cancer Research
4. Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer
   Haifeng Shen, Yichen Jin, Heng Zhao, Manqi Wu, Kai Zhang, Zihan Wei, Xin Wang, Ziyang Wang, Yun Li, Fan Yang et al. · 2022 · BMC Medicine
5. Recurrence After Complete Resection for Non-Small Cell Lung Cancer in the National Lung Screening Trial
   Alexandra L. Potter, Christina L. Costantino, Raiya A. Suliman, Chinmay Haridas, Priyanka Senthil, Arvind Kumar, Nicholas R. Mayne, Nikhil Panda, Linda W. Martin, Chi‐Fu Jeffrey Yang · 2023 · The Annals of Thoracic Surgery
6. Escape from T-cell–targeting immunotherapies in acute myeloid leukemia
   Jayakumar Narayanan Vadakekolathu, Sergio Rutella · 2023 · Blood
7. Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities
   Jessica Marie Konen, Haoyi Wu, Don Lynn Gibbons · 2024 · Trends in Pharmacological Sciences
8. Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution
   Calixto‐Hope G. Lucas, Kanish Mirchia, Kyounghee Seo, Hinda Najem, William Chen, Naomi Zakimi, Kyla J. Foster, Charlotte D. Eaton, Martha A. Cady, Abrar Choudhury et al. · 2024 · Nature Genetics
9. Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer
   Chaoyuan Liu, Wei Zhao, Junpeng Xie, Huashan Lin, Xingsheng Hu, Chang Li, Youlan Shang, Yapeng Wang, Yingjia Jiang, Meng-Ge Ding et al. · 2023 · Frontiers in Immunology
10. Regulatory implications of ctDNA in immuno-oncology for solid tumors
    Paz J. Vellanki, Soma Ghosh, Anand Pathak, Michael J. Fusco, Erik W. Bloomquist, Shenghui W. Tang, Harpreet Singh, Reena Philip, Richard Pazdur, Julia A. Beaver · 2023 · Journal for ImmunoTherapy of Cancer
11. Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial
    Qing Hua Zhou, Yi Pan, Xue‐Ning Yang, Yanqiu Zhao, Guang Han, Qingsong Pang, Zhenfa Zhang, Qifeng Wang, Jun Yao, Hui Wang et al. · 2024 · Cancer Cell
12. The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-small Cell Lung Cancer
    Samuel S. Kim, David Tom Cooke, Biniam Kidane, Luis F. Tapias, John Franklin Leopold Lazar, J.W. Awori Hayanga, Jyoti D. Patel, Joel W. Neal, Mohamed E. Abazeed, Henning Willers et al. · 2024 · The Annals of Thoracic Surgery
13. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions
    Xiaoyu Gang, Jinshan Yan, Xin Li, Sha Shi, Lu Xu, Ruotong Mona Liu, Lutong Cai, Heming Li, Mingfang Zhao · 2024 · Cancer Letters
14. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
    Marta Casarrubios, Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García-Campelo, Martín Lázaro-Quintela, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí et al. · 2022 · Journal for ImmunoTherapy of Cancer
15. A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer
    Ernest Nadal, Mansoor Noorali Saleh, Santiago Ponce-Aix, María Ochoa-de-Olza, Sandip Pravin Patel, Scott Joseph Antonia, Yumin Zhao, Ivelina Gueorguieva, Michael Z. Man, Shawn T. Estrem et al. · 2023 · BMC Cancer
16. Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy
    Elkrief, Arielle, Méndez-Salazar, Eder Orlando, Maillou, Jade, Vanderbilt, Chad M., Gogia, Pooja, Desilets, Antoine, Messaoudene, Meriem, Kelly, Daniel, Ladanyi, Marc, Hellmann, Matthew D. et al. · 2024 · npj Precision Oncology
17. Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial
    Virginie Westeel, Pascal Foucher, Arnaud Scherpereel, Jean Domas, Philippe Girard, Jean Trédaniel, Marie Wislez, Patrick Dumont, Élisabeth Quoix, Olivier Raffy et al. · 2022 · The Lancet Oncology
18. Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers
    Satoshi Muto, Akio Enta, Yoshiyuki Maruya, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Yuki Ozaki, Masayuki Watanabe, Takuya Inoue et al. · 2023 · Biomedicines
19. Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-Analysis
    Natthaya Triphuridet, Shannon S. Zhang, Misako Nagasaka, Yanfei Gao, Joseph Jonathan Zhao, Nicholas L. X. Syn, Takaomi Hanaoka, Sai‐Hong Ignatius Ou, Elaine Shum · 2023 · Journal of Thoracic Oncology
20. Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review
    Alejandro Olivares-Hernández, Elisabet González-Del Portillo, Álvaro Tamayo-Velasco, Luis Figuero-Pérez, Svetlana Zhilina-Zhilina, Emilio Fonseca‐Sánchez, José Pablo Miramontes‐González · 2023 · Annals of Translational Medicine
21. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
    Xinsheng Zhu, Liangdong Sun, Nan Song, Wenxin He, Boxiong Xie, Junjie Hu, Jing Zhang, Jie Yang, Jie Dai, Dongliang Bian et al. · 2022 · BMC Medicine
22. Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
    Anushka Walia, Jordan E. Tuia, Vinay K. Prasad · 2023 · Nature Reviews Clinical Oncology
23. Surgical margins in head and neck squamous cell carcinoma: A narrative review
    Yang Chen, Nian‐Nian Zhong, Lei‐Ming Cao, Bing Liu, Lin‐Lin Bu · 2024 · International Journal of Surgery
24. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC
    Yixin Zhou, Anlin Li, Hui Yu, Yuhong Wang, Xuanye Zhang, Huijuan Qiu, Wei Ting Du, Linfeng Luo, Sha Fu, Li Zhang et al. · 2024 · JAMA Network Open
25. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Overview of Challenges and Opportunities in Revising the Nodal Classification of Lung Cancer
    Raymond Uyiosa Osarogiagbon, Paul E. Van Schil, Dorothy J. Giroux, Eric Kian Saik Lim, Paul Martin Putora, Yolande N. Lievens, Giuseppe Cardillo, Hong Kwan Kim, Gaetano Rocco, Andrea Billè et al. · 2022 · Journal of Thoracic Oncology
26. Potential Applications of Nanoparticles in Improving the Outcome of Lung Cancer Treatment
    Agnishwar Girigoswami, Koyeli Girigoswami · 2023 · Genes
27. Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer
    Christopher Abbosh, Darren Hodgson, Gary Joseph Doherty, Davina Gillian Gale, James R. Black, Leora Horn, Jorge Sergio Reis-Filho, Charles Swanton · 2024 · Trends in cancer
28. An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer
    Ilias Houda, Idris Bahce, Chris Dickhoff, Tiuri Ewout Kroese, Stephanie G. C. Kroeze, Alessio Vincenzo Mariolo, Marco Tagliamento, Laura Moliner, Mariana Brandão, Yassin Pretzenbacher et al. · 2024 · Lung Cancer
29. Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer
    Yu Wang, Tao Zhang, Jianyang Wang, Zongmei Zhou, Wenyang Liu, Zefen Xiao, Lei Deng, Qinfu Feng, Xin Wang, Jima Lv et al. · 2023 · International Journal of Radiation Oncology*Biology*Physics
30. Extraction, purification, structural characterization and pharmacological activities of polysaccharides from sea buckthorn (Hippophae rhamnoides L.): A review
    Hao Teng, Zhigui He, Cheng-Zhi Hong, Song-Zi Xie, Xue‐Qiang Zha · 2024 · Journal of Ethnopharmacology
31. Management of Patients With Early-Stage Non-Small Cell Lung Cancer
    John Howington, Lesley Souter, Douglas A. Arenberg, Justin David Blasberg, Frank C. Detterbeck, Farhood Farjah, Michael D. Lanuti, Natasha B. Leighl, Gregory M.M. Videtic, Sudish Murthy · 2025 · CHEST Journal
32. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
    Tricia R. Cottrell, Michael T. Lotze, Alaa Mohammed Ali, Carlo Bruno Bifulco, Christian M. Capitini, Laura Q.M. Chow, Anthony Richard Cillo, Deborah E. Collyar, Leslie Cope, Julie Stein Deutsch et al. · 2025 · Journal for ImmunoTherapy of Cancer
33. Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review
    Molly Siu Ching Li, Kevin K. S. Mok, Tony S.K. Mok · 2023 · Annals of Translational Medicine
34. Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
    Luis A. Godoy, Joy Chen, Weijie Ma, Jag Lally, Kyra A. Toomey, Prabhu Rajappa, Roya Sheridan, Shirish Mahajan, Nicholas S. Stollenwerk, Chinh T. Phan et al. · 2023 · Biomarker Research
35. Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy
    Muhua Chen, Lei Bie, Jieer Ying · 2023 · Biomedicine & Pharmacotherapy
36. Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial
    Yan Zheng, Guanghui Liang, Dongfeng Yuan, Xianben Liu, Yufeng Ba, Zimin Qin, Sining Shen, Zhenxuan Li, Haibo Sun, Baoxing Liu et al. · 2024 · 癌症：英文版
37. Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities
    Huiyu Wang, Xiaomin Niu, Zhenning Jin, Shaoxing Zhang, Rong Fan, Hua Xiao, Song Hu · 2025 · Journal of Experimental & Clinical Cancer Research
38. Spatially mapping the tumour immune microenvironments of non-small cell lung cancer
    Lysanne Desharnais, Mark Sorin, Morteza Rezanejad, Bridget Liu, Elham Karimi, Aline Atallah, Anikka M. Swaby, Miranda W. Yu, Samuel Doré, Saskia Hartner et al. · 2025 · Nature Communications
39. Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
    Ren Luo, Kateryna Onyshchenko, Liqun Wang, Simone Gaedicke, Anca‐Ligia Grosu, Elke Firat, Gabriele Niedermann · 2022 · Clinical Cancer Research
40. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma
    Camilla Di Dio, Giorgio Bogani, Violante Di Donato, Ilaria Cuccu, Ludovico Muzii, Lucia Musacchio, Giovanni Scambia, Domenica Lorusso · 2022 · Gynecologic Oncology
41. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer
    Fabrice Barlési, Byoung Chul Cho, Sarah B. Goldberg, Kiyotaka Yoh, Ana Caroline Zimmer Gelatti, Helen Mann, Aarthi Gopinathan, Zofia Felicja Bielecka, Michael Newton, Charu Aggarwal · 2024 · Future Oncology
42. Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
    Nicola Normanno, Alessandro Morabito, Anna Maria Rachiglio, Vincenzo Sforza, Lorenza Maria Landi, Emilio Bria, Angelo Delmonte, Federico Cappuzzo, Antonella De Luca · 2025 · Nature Reviews Clinical Oncology
43. Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis
    Samuel Rosner, Chunnan Liu, Patrick M. Forde, Chen Hu · 2022 · JTO Clinical and Research Reports
44. Neoadjuvant immunotherapy for resectable esophageal cancer: A review
    Qing Li, Ting Liu, Zhenyu Ding · 2022 · Frontiers in Immunology
45. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
    Alessandro Di Federico, Stephanie Leigh Alden, James William Smithy, Biagio Ricciuti, Joao V. Alessi, Xinan Wang, Federica Pecci, Giuseppe Lamberti, Malini Marion Gandhi, Victor R. Vaz et al. · 2024 · Annals of Oncology
46. Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy
    Mariano Provencio, Virginia Calvo, Atocha Romero, Jonathan David Spicer, Alberto Cruz‐Bermúdez · 2022 · American Society of Clinical Oncology Educational Book
47. Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future
    Amit G. Singal, Mark M. Yarchoan, Adam Charles Yopp, Gonzalo Sapisochín, David James Pinato, Anjana A Pillai · 2024 · Hepatology Communications
48. Prediction of brain metastasis development with DNA methylation signatures
    Jeffrey Zuccato, Yasin Mamatjan, Farshad Nassiri, Andrew A. Ajisebutu, Jeffrey Liu, Ammara Muazzam, Olivia Singh, Wen Zhang, Mathew Ryan Voisin, Shideh Mirhadi et al. · 2024 · Nature Medicine
49. Liquid biopsies across the cancer care continuum
    Blair V. Landon, Akshaya Vijaya Annapragada, Noushin Niknafs, Victor E. Velculescu, Valsamo Anagnostou · 2025 · Nature Medicine
50. Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial
    Jun Zhao, Liang Zhao, Wei Guo, Shuhang Wang, Xiuli Tao, Lin Li, Yousheng Mao, Fengwei Tan, Yushun Gao, Ning Wu et al. · 2023 · Journal of Thoracic Oncology
51. Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers
    Javier Ros, Iosune Baraibar, Nadia Saoudi Gonzalez, Marta Rodríguez-Castells, Francesc Salvà, Josep M. Tabernero, Elena Élez · 2023 · Cancers
52. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy
    Sanja Đačić, William David Travis, Mary Weber Redman, Anjali Saqi, Wendy A. Cooper, Alain Borczuk, Jin-Haeng Chung, Carolyn Glass, Javier Martín-López, Anja Christiane Roden et al. · 2023 · Journal of Thoracic Oncology
53. Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy
    Valsamo Anagnostou, Blair V. Landon, Jamie E. Medina, Patrick M. Forde, Victor E. Velculescu · 2022 · Science Translational Medicine
54. Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial
    Miner Shao, Jie Yao, Yunke Wang, Lufeng Zhao, Baizhou Li, Lili Li, Zuqun Wu, Zexin Chen, Junqiang Fan, Fuming Qiu · 2023 · Signal Transduction and Targeted Therapy
55. Lung cancer research and treatment: global perspectives and strategic calls to action
    May‐Lucie Meyer, Solange Peters, Tony S.K. Mok, Stephen C. Lam, Pan‐Chyr Yang, C. Aggarwal, Julie Renee Brahmer, Rafał Dziadziuszko, Enriqueta Felip, Andrea A. Ferris et al. · 2024 · Annals of Oncology
56. Adjuvant and neoadjuvant therapies for hepatocellular carcinoma
    Arndt Vogel, Robert C. Grant, Tim Meyer, Gonzalo Sapisochín, Grainne Mary O'Kane, Anna Lena Saborowski · 2023 · Hepatology
57. Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs
    Qing Liao, Ximing Zhou, Ling Wu, Yuyi Yang, Xiaohui Zhu, Hangyu Liao, Yujie Zhang, Weidong Lian, Feifei Zhang, Hui Wang et al. · 2025 · Journal of Clinical Investigation
58. Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non–Small-Cell Lung Cancer
    Antonio Passaro, Ilaria Attili, Filippo de Marinis · 2022 · Journal of Clinical Oncology
59. Perioperative Immune Checkpoint Inhibition in Early-Stage Non–Small Cell Lung Cancer
    Aakash P. Desai, Jacob J. Adashek, Joshua E. Reuss, Howard West, Aaron Scott Mansfield · 2022 · JAMA Oncology
60. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives
    Chiara Lazzari, Calogera Claudia Spagnolo, Giuliana Ciappina, Martina Di Pietro, Andrea Squeri, Maria Ilenia Passalacqua, Silvia Marchesi, Vanesa Gregorc, Mariacarmela Santarpía · 2023 · Current Oncology
61. Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy
    Shiying Fan, Zhengting Jiang, Zhilin Zhang, Juan Xing, Daorong Wang, Dong Tang · 2023 · Journal of Cancer Research and Clinical Oncology
62. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
    Tina Cascone, Laura Bonanno, Florian Guisier, Amelia Insa, Moïshe Liberman, Olivier Bylicki, Lorenzo Livi, Thomas Egenod, R. Corre, Dong‐Wan Kim et al. · 2025 · Nature Medicine
63. Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
    Dongliang Bian, Liangdong Sun, Junjie Hu, Liang Duan, Haoran Xia, Xinsheng Zhu, Fenghuan Sun, Lele Zhang, Huansha Yu, Yicheng Xiong et al. · 2023 · Nature Communications
64. T cell dynamics with neoadjuvant immunotherapy in head and neck cancer
    Maryann Zhao, Jonathan Daniel Schoenfeld, Ann Marie Egloff, Glenn J. Hanna, Robert I. Haddad, Douglas R. Adkins, Ravindra Uppaluri · 2024 · Nature Reviews Clinical Oncology
65. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
    Naiyer A. Rizvi, Foluso Olabisi Ademuyiwa, Zhu Alexander Cao, Helen X. Chen, Robert Louis Ferris, Sarah B. Goldberg, Matthew David Hellmann, Ranee Mehra, Ina Park Rhee, Jong Chul Park et al. · 2023 · Journal for ImmunoTherapy of Cancer
66. Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations
    Leilei Wu, Zhenshan Zhang, Menglin Bai, Yujie Yan, Jinming Yu, Yaping Xu · 2023 · Cell Communication and Signaling
67. Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer
    Christopher Grant, Misako Nagasaka · 2024 · Cancer Treatment Reviews
68. Targeted therapeutic options in early and metastatic NSCLC-overview
    Gabriella Gálffy, Éva Mórocz, Réka Korompay, Réka Hécz, Réka Bujdosó, Rita Puskás, Tímea Lovas, Eszter Gáspár, Kamel Yahya, Péter Attila Király et al. · 2024 · Pathology & Oncology Research
69. Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
    Joline Ingels, Laurenz De Cock, Dieter Stevens, Rupert Laurenz Mayer, Fabien Théry, Guillem Sanchez Sanchez, David Vermijlen, Karin Weening, Saskia De Smet, Nele Lootens et al. · 2024 · Cell Reports Medicine
70. Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis
    Daniele Marinelli, Antonio Nuccio, Alessandro Di Federico, Francesca Ambrosi, Pietro Bertoglio, Eleonora Faccioli, Roberto Ferrara, Alessandra Ferro, Raffaele Giusti, Francesco Guerrera et al. · 2024 · Journal of Thoracic Oncology
71. Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis
    Carmine Valenza, Erick Figueiredo Saldanha, Y. Gong, Pietro De Placido, David Gritsch, H. Ortiz, Dario Trapani, Fabio Conforti, Chiara Cremolini, S. Peters et al. · 2025 · Annals of Oncology
72. Neoadjuvant therapy in non-small cell lung cancer
    Christopher Grant, Garo Greg Hagopian, Misako Nagasaka · 2023 · Critical Reviews in Oncology/Hematology
73. Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer
    Joseph Christopher Murray, Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James Robert White, Noushin Niknafs, Lamia Rhymee, Gavin Pereira, Nisha Rao, Benny Weksler et al. · 2023 · Clinical Cancer Research
74. MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC
    Martin Reck, Ernest Nadal, Nicolas Girard, Andrea Riccardo Filippi, Linda W. Martin, Carl Michael Gay, Cordula Petersen, Davina Gillian Gale, Ugochinyere A. Emeribe, Nefeli Georgoulia et al. · 2024 · Clinical Lung Cancer
75. Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab
    Tyler Joseph Alban, Nadeem Riaz, Prerana Bangalore Parthasarathy, Vladimir Makarov, Sviatoslav M. Kendall, Seong‐Keun Yoo, Rachna Shah, Nils Weinhold, Raghvendra Mohan Srivastava, Xiaoxiao Ma et al. · 2024 · Nature Medicine
76. Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
    Mark Magdi Awad, Patrick M. Forde, Nicolas Girard, Jonathan David Spicer, Changli Wang, Shun Lü, Tetsuya Mitsudomi, Enriqueta Felip, Stephen Broderick, Steven Swanson et al. · 2025 · Journal of Clinical Oncology
77. The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
    Gil Awada, Tina Cascone, Michiel S. van der Heijden, Christian U. Blank, Marleen Kok, Myriam Chalabi · 2025 · Nature Cancer
78. Current and Future Treatment Options in the Management of Stage III NSCLC
    Yuchen Li, Rosalyn Anne Juergens, Christian Finley, Anand Swaminath · 2023 · Journal of Thoracic Oncology
79. Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
    Si‐Yang Liu, Song Dong, Xue‐Ning Yang, Ri-Qiang Liao, Ben‐Yuan Jiang, Qun Wang, Xiaosong Ben, Guibin Qiao, Jun‐Tao Lin, Hong‐Hong Yan et al. · 2023 · Signal Transduction and Targeted Therapy
80. Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer
    Arianna Marinello, Marco Tagliamento, Arianna Pagliaro, Nicole Conci, Eugenia Cella, Damien Vasseur, Jordi Remón, Antonin Lévy, Filippo Gustavo Dall’Olio, Benjamin Besse · 2024 · Cancer Treatment Reviews
81. Biomarkers for immunotherapy resistance in non-small cell lung cancer
    Catriona Rother, Tom John, Annie Ngai Man Wong · 2024 · Frontiers in Oncology
82. Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation
    Zachary Scott Morris, Sandra Demaria, Arta Monir Monjazeb, Silvia Chiara Formenti, Ralph R. Weichselbaum, James D. Welsh, Heiko Enderling, Jonathan Daniel Schoenfeld, Joshua Brody, Heather M. McGee et al. · 2025 · The Lancet Oncology
83. A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer
    Aristeidis E. Boukouris, Kleita Michaelidou, Simon Andreas Joosse, Andriani G. Charpidou, Dimitriοs Mavroudis, Konstantinos Nikolaos Syrigos, Sofia Agelaki · 2025 · npj Precision Oncology
84. Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone
    Wen‐Fang Tang, Hong-Yu Ye, Xuan Tang, Jianwei Su, Kang-Mei Xu, Wen‐Zhao Zhong, Yi Liang · 2023 · Frontiers in Oncology
85. Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best‐practice guide
    Adam H. Fox, Mizuki Nishino, Raymond Uyiosa Osarogiagbon, M. Patricia Rivera, Lauren S. Rosenthal, Robert Allen Smith, Farhood Farjah, Lynette Marie Sholl, Gerard A. Silvestri, Bruce Evan Johnson · 2023 · CA A Cancer Journal for Clinicians
86. Lymph nodes: at the intersection of cancer treatment and progression
    Nathan Edward Reticker-Flynn, Edgar G. Engleman · 2023 · Trends in Cell Biology
87. Intratumoral CD103 + CD8 + T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma
    Siqi Ren, Tianjun Lan, Fan Wu, Suling Chen, Xue Jiang, Chuying Huo, Zitian Li, Shule Xie, Donghui Wu, Ruixin Wang et al. · 2023 · 癌症：英文版
88. LIBRETTO-432, a Phase III Study of Adjuvant Selpercatinib or Placebo in Stage IB-IIIA RET Fusion-Positive Non-Small-Cell Lung Cancer
    Masahiro Tsuboi, Jonathan Wade Goldman, Yi-Long Lung Cancer Wu, Melissa Lynne Johnson, Luis G Paz-Ares, James Chih‐Hsin Yang, Benjamin Besse, Weiji Su, Bo H. Chao, Alexander Edward Dela Cruz Drilon · 2022 · Future Oncology
89. US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer
    Oladimeji Akinboro, Nicole Lauren Drezner, Anup K. Amatya, Runyan Jin, Jeanne Fourie Zirkelbach, Miao Zhao, Youwei Bi, Kwadwo Korsah, Bronwyn D. Mixter, Shenghui W. Tang et al. · 2023 · Journal of Clinical Oncology
90. Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)
    Chao Zhang, Yu-Xuan Sun, Dingcheng Yi, Ben‐Yuan Jiang, Li‐Xu Yan, Ze-Dao Liu, Lishan Peng, Wenjie Zhang, Hao Sun, Zhiyong Chen et al. · 2024 · Cell Reports Medicine
91. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer
    Valerie W. Rusch, Alan Nicholas, G. Alexander Patterson, Salama N. Waqar, Eric M. Toloza, Eric B. Haura, Dan J. Raz, Karen L. Reckamp, Robert E. Merritt, Dwight Hall Owen et al. · 2022 · Journal of Thoracic and Cardiovascular Surgery
92. A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma
    Shetal Arvind Patel, Michael K. Gibson, Allison Mary Deal, Siddharth H Sheth, Hillary Heiling, Steven M. Johnson, Kathe Douglas, Melissa Flores, Jeffrey M. Blumberg, Catherine J. Lumley et al. · 2023 · Cancer
93. Single-cell sequencing on CD8+ TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer
    Hiroyasu Komuro, Shuichi Shinohara, Yasunori Fukushima, Ayako Demachi‐Okamura, Daisuke Muraoka, Katsuhiro Masago, Takuya Matsui, Yusuke Sugita, Yusuke Takahashi, Reina Nishida et al. · 2023 · Journal for ImmunoTherapy of Cancer
94. Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
    Annapaola Mariniello, Tahseen H. Nasti, Daniel Y. Chang, Masao Hashimoto, Sakshi Malik, Daniel Thomas McManus, Judong Lee, Donald J. McGuire, Maria Andrea Cardenas, Pablo Umaña et al. · 2023 · Clinical Cancer Research
95. Cisplatin in the era of PARP inhibitors and immunotherapy
    Mingrui Duan, Shuguang Leng, Peng Mao · 2024 · Pharmacology & Therapeutics
96. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
    Heng‐Chung Kung, Jun Yu · 2023 · MedComm
97. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis
    Yujia Chen, Jianjun Qin, Yajing Wu, Qiang Lin, Jianing Wang, Wei Zhang, Fei Liang, Zhouguang Hui, Min Zhao, Jun Wang · 2023 · International Journal of Surgery
98. Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis
    Wen-Yu Zhai, Ze-Rui Zhao, Si Chen, Hui Yu, Yaobin Lin, Yizhi Wang, Hao Long · 2022 · Journal for ImmunoTherapy of Cancer
99. Immune-related adverse events of neoadjuvant immunotherapy in patients with perioperative cancer: a machine-learning-driven, decade-long informatics investigation
    Song‐Bin Guo, Dengyao Liu, Rong Hu, Zhen-Zhong Zhou, Meng Yuan, Hai-Long Li, Weijuan Huang, Xiao‐Peng Tian · 2025 · Journal for ImmunoTherapy of Cancer
100. Early-stage ALK-positive lung cancer: a narrative review
     Monica F. Chen, Jamie E. Chaft · 2023 · Translational Lung Cancer Research